Novel ellagitannins and oral preparations

Novel ellagitannins from sweet tea extract address xerostomia and plaque formation by promoting aquaporin and serine palmitoyltransferase expression, enhancing saliva and lacrimal gland secretion, and inhibiting plaque, thus improving oral and skin health.

JP7577351B2Active Publication Date: 2024-11-05MARUZEN PHARMA
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
JP2022198159
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-09-09
Filing Date
2022-12-12
Publication Date
2024-11-05
Estimated Expiration
2036-07-29

AI Technical Summary

Technical Problem

Current treatments for xerostomia, such as gargles and oral ointments, only provide temporary moisture and do not address the underlying issue of reduced saliva secretion, while plaque formation leads to dental caries, and skin dryness results in barrier function loss, lacking effective promoters for aquaporin and serine palmitoyltransferase expression.

Method used

Isolation and identification of novel ellagitannins from sweet tea extract that promote aquaporin 5 and 3 mRNA expression, inhibit plaque formation, and enhance serine palmitoyltransferase expression, formulated into oral compositions and food/beverage products.

Benefits of technology

The ellagitannins effectively promote saliva and lacrimal gland secretion, inhibit plaque formation, and strengthen skin barrier function, providing long-term relief for xerostomia, dry mouth symptoms, and preventing dental caries and skin dryness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577351000001
    Figure 0007577351000001
  • Figure 0007577351000002
    Figure 0007577351000002
  • Figure 0007577351000003
    Figure 0007577351000003
Patent Text Reader

Abstract

The present invention provides novel ellagitannins, APQ5 mRNA expression promoters, APQ3 mRNA expression promoters, plaque formation inhibitors, and SPT mRNA expression promoters with excellent effects. [Solution] The active ingredients include a novel ellagitannin exemplified by the following compound (I-3), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract. TIFF2023027253000026.tif59159
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel ellagitannin, an aquaporin 5 mRNA expression promoter, an aquaporin 3 mRNA expression promoter, a plaque formation inhibitor, a serine palmitoyltransferase mRNA expression promoter, an oral preparation, and a food and drink product. [Background technology]

[0002] Xerostomia, also known as dry mouth, is a disease in which saliva secretion is reduced. There are various causes of xerostomia, including aging, stress, poor diet, smoking, salivary gland disorders, symptoms of systemic diseases such as Sjögren's syndrome, and side effects of drugs. When xerostomia is contracted, in the early stages, a sticky feeling in the mouth, increased plaque, tongue coating, and bad breath occur, and when the symptoms become severe, glossodynia, dysphagia, stomatitis, angular cheilitis, severe bad breath, periodontal disease, and the like occur. Mouthwashes, lozenges, oral ointments, mouthwashes, and the like are used to treat xerostomia, but these can only temporarily moisten the oral cavity.

[0003] Water, which is the major component of saliva, is supplied by epithelial cells in the salivary glands. Water channels called aquaporins (AQPs) are localized in the cell membranes of epithelial cells, increasing water permeability. Aquaporins are membrane proteins with six transmembrane domains, and 13 types of aquaporins (AQP0-AQP12) are known to exist in humans. Of these, AQP5 is localized in the apical membrane of acinar cells in the salivary glands and contributes to water secretion into the acini, while AQP3 is localized in the basolateral and lateral walls of acinar cells and contributes to water inflow into acinar cells.

[0004] Cevimeline hydrochloride is known as a therapeutic agent for xerostomia in patients with Sjogren's syndrome. It has been reported that cevimeline hydrochloride stimulates muscarinic receptors in salivary gland cells and localizes AQP5 to the apical membrane (see Non-Patent Document 1), and is considered to promote saliva secretion through the localization of AQP5 to the apical membrane. Therefore, if the expression of AQP5 can be enhanced, it is considered that saliva secretion can be promoted and xerostomia can be treated or improved.

[0005] Furthermore, if AQP3 expression can be promoted, it is believed that water inflow into acinar cells will be promoted, thereby promoting water secretion from the apical membrane of acinar cells to the acini of the salivary gland, thereby treating or ameliorating xerostomia.

[0006] Components that promote the expression of AQP5 include retinoic acid (see Patent Document 1), pineapple ceramide (see Patent Document 2), etc. Components that promote the expression of AQP3 include star fruit leaf extract (see Patent Document 3), shell ginger extract (see Patent Document 4), etc.

[0007] Oral microorganisms such as Streptococcus mutans are involved in the development of dental caries. In other words, some of the sucrose in food and drink remaining in the mouth is converted into water-insoluble, highly adhesive glucan, which adheres to the tooth surface together with oral microorganisms to form plaque. The microorganisms in the plaque then metabolize the sugar in food and drink to produce acid, which demineralizes and erodes the tooth enamel, resulting in dental caries.

[0008] Therefore, in order to prevent dental caries, it is most effective not only to remove plaque attached to the tooth surface by brushing the teeth, but also to prevent plaque from forming. As ingredients that inhibit plaque formation, extracts of peanut astringent skin (see Patent Document 5), wild grape extracts (see Patent Document 6), etc. are known.

[0009] Ceramide is produced from serine and palmitoyl-CoA by the action of enzymes including serine palmitoyltransferase (SPT), known as the rate-limiting enzyme in ceramide synthesis. Ceramide is specifically present as the main component of intercellular lipids that cover the outermost layer of the skin, and plays an important role in maintaining the skin's inherent function as a barrier membrane between the body and the outside world.

[0010] A decrease in the skin's barrier function due to various internal and external factors increases transepidermal water loss, causing dry skin, scaling, itching, etc. A decrease in the skin's barrier function also increases inflammation of the skin, resulting in a vicious cycle in which the skin's defense against various external stimuli is reduced.

[0011] Therefore, it is considered that the barrier function of the skin can be maintained by, for example, promoting the expression of SPT in order to enhance the ability to produce ceramide. In addition to the star fruit leaf extract (see Patent Document 4) described above, Acer palmatum extract (see Patent Document 7) and the like are known as ingredients that promote the expression of SPT. [Prior art documents] [Patent documents]

[0012] [Patent Document 1] JP 2007-332048 A [Patent Document 2] JP 2014-169238 A [Patent Document 3] JP 2009-191039 A [Patent Document 4] JP 2012-219031 A [Patent Document 5] JP 2000-178158 A [Patent Document 6] JP 2005-082568 A [Patent Document 7] JP 2011-068594 A [Non-patent literature]

[0013] [Non-Patent Document 1] Ishikawa Y. et al., FEBS Lett., vol.477, pp.253-257 (2000) Summary of the Invention [Problem to be solved by the invention]

[0014] The present invention aims to provide novel compounds having various effects, aquaporin 5 mRNA expression promoters, aquaporin 3 mRNA expression promoters, plaque formation inhibitors, serine palmitoyltransferase mRNA expression promoters, oral compositions, and foods and beverages with excellent effects. [Means for solving the problem]

[0015] The present inventors have succeeded in isolating and identifying novel ellagitannins having the action of promoting aquaporin 5 mRNA expression, aquaporin 3 mRNA expression, or serine palmitoyltransferase mRNA expression from a sweet tea extract. Furthermore, the present inventors have isolated compounds having the action of promoting aquaporin 5 mRNA expression, aquaporin 3 mRNA expression, plaque formation inhibitory action, or serine palmitoyltransferase mRNA expression from among the components contained in a sweet tea extract, thereby completing the present invention.

[0016] That is, first, the present invention provides a novel ellagitannin represented by the following formula (I) (Inventions 1 to 4).

[0017] [ka]

[0018] In formula (I), HHDP is a hexahydroxydiphenoyl group represented by the following formula (Ia): [ka] Sang is a sangisoluboyl group represented by the following formula (Ib). [ka]

[0019] Secondly, the present invention provides an aquaporin 5 mRNA expression promoter (Invention 5), an aquaporin 3 mRNA expression promoter (Invention 6), a plaque formation inhibitor (Invention 7), and a serine palmitoyltransferase mRNA expression promoter (Invention 8), which are characterized by having as an active ingredient the ellagitannin, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract according to the above inventions (Inventions 1 to 4).

[0020] Thirdly, the present invention provides an oral composition (Invention 9) and a food or beverage (Invention 10) characterized by containing the ellagitannin according to any of the above inventions (Inventions 1 to 4), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract. Effect of the Invention

[0021] According to the present invention, a novel ellagitannin represented by the above formula (I) is provided, which is obtained from a highly safe natural product and has excellent aquaporin 5 mRNA expression promoting activity, aquaporin 3 mRNA expression promoting activity, plaque formation inhibitory activity, and serine palmitoyltransferase mRNA expression promoting activity.

[0022] In addition, according to the present invention, it is possible to provide an aquaporin 5 mRNA expression promoter, an aquaporin 3 mRNA expression promoter, a plaque formation inhibitor, and a serine palmitoyltransferase mRNA expression promoter with excellent action and effect. Furthermore, according to the present invention, it is possible to provide an oral composition and a food and drink that are excellent in the aquaporin 5 mRNA expression promoting action, the aquaporin 3 mRNA expression promoting action, the plaque formation inhibiting action, or the serine palmitoyltransferase mRNA expression promoting action. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Hereinafter, an embodiment of the present invention will be described. [New ellagitannin] The ellagitannin of the present embodiment is represented by the following formula (I).

[0024] [ka]

[0025] In formula (I), HHDP is a hexahydroxydiphenoyl group represented by the following formula (Ia): [ka] Sang is a sangisoluboyl group represented by the following formula (Ib). [ka]

[0026] Hereinafter, the ellagitannin represented by 1 in the above formula (I) will be referred to as "brambliin A," the ellagitannin represented by 2 in the above formula (I) will be referred to as "brambliin B," the ellagitannin represented by 3 in the above formula (I) will be referred to as "brambliin C," and the ellagitannin represented by 4 in the above formula (I) will be referred to as "brambliin D."

[0027] It has been confirmed in the examples described below that Branbulyin A has the structure 1-O-galloyl-4,6-O-[3-[2,3-dihydroxy-5-[2,3-O-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl-β-D-glucopyranosyloxycarbonyl]phenoxy]-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl]-β-D-glucopyranose, represented by 1 in the above formula (I).

[0028] It has been confirmed in the examples described below that Branbulyin B has the structure 1-O-galloyl-2,3-O-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl-4,6-O-[3-[2,3-dihydroxy-5-[2,3-O-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl-β-D-glucopyranosyloxycarbonyl]phenoxy]-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl]-β-D-glucopyranose, represented by 2 in the above formula (I).

[0029] It has been confirmed in the Examples described below that Branbulyin C has the structure 1-O-galloyl-2,3-O-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl-4,6-O-[3-[2,3-dihydroxy-5-[4,6-O-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl-β-D-glucopyranosyloxycarbonyl]phenoxy]-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl]-β-D-glucopyranose, represented by 3 in the above formula (I).

[0030] Branburin D is 1-O-galloyl-2,3-O-[4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl]-4,6-O-[3-[2,3-dihydroxy-5-[2,3-O-[4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl]-4,6-O-[3-(5-carboxy-2,3- It has been confirmed in the Examples described below that the compound has the structure: [4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarboxyl]-β-D-glucopyranosyloxycarbonyl]phenoxy]-4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diylbiscarbonyl]-β-D-glucopyranose.

[0031] Branbulyins A to D are novel substances isolated from sweet tea (Rubus suavissimus).

[0032] Brambulines A to D can be isolated from Tencha, but may also be present in plants other than Tencha, such as Rubus coreanum, Rubus lambertianus, Rubus ulmifolius, and Rubus coreanum, which belong to the same Rubus genus of the Rosaceae family as Tencha. Therefore, the isolation source of brambulines A to D is not limited to Tencha, and any plant containing brambulines A to D may be used.

[0033] Branbuliins A to D can be obtained, for example, by subjecting a sweet tea extract to purification procedures effective for isolating ellagitannins, such as liquid-liquid partition extraction, various types of chromatography, membrane separation, recrystallization, etc., and then performing liquid chromatography treatment using octadecylsilylated silica gel (ODS) or the like as a stationary phase.

[0034] Specifically, branbuline A to D can be obtained by the following steps (a) to (c). Process (a) Step (a) is a step of subjecting Tencha to extraction treatment with water, a hydrophilic organic solvent or a mixed solvent thereof to obtain a Tencha extract.

[0035] Rubus suavissimus is a shrub belonging to the genus Rubus in the family Rosaceae, and grows wild in southern China, where it can be easily obtained. The parts that can be used as the raw material for extraction include leaves, stems, flowers, fruits, and other aboveground parts, and roots, and other underground parts. Although not particularly limited, leaves are preferred. Traditionally, extracts of Rubus suavissimus have been used as antiallergic agents, etc.

[0036] The extract from sweet tea can be obtained by drying the raw material for extraction, and then subjecting it to extraction with an extraction solvent, either directly or after crushing using a crusher. Drying can be performed in the sun or using a commonly used dryer. In addition, the raw material for extraction may be subjected to pretreatment such as degreasing with a non-polar solvent such as hexane before use. By performing pretreatment such as degreasing, the extraction process of sweet tea with a polar solvent can be performed efficiently.

[0037] As the extraction solvent, it is preferable to use a polar solvent, such as water or a hydrophilic organic solvent, which is preferably used alone or in combination of two or more at room temperature or at a temperature below the boiling point of the solvent.

[0038] Water that can be used as an extraction solvent includes pure water, tap water, well water, mineral water, hot spring water, spring water, fresh water, etc., as well as water that has been subjected to various treatments. Treatments that can be applied to water include, for example, purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, etc. Therefore, water that can be used as an extraction solvent in this embodiment also includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered physiological saline, etc.

[0039] Examples of hydrophilic organic solvents that can be used as the extraction solvent include lower aliphatic alcohols having 1 to 5 carbon atoms, such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones, such as acetone and methyl ethyl ketone; and polyhydric alcohols having 2 to 5 carbon atoms, such as 1,3-butylene glycol, propylene glycol, and glycerin.

[0040] When a mixture of two or more polar solvents is used as an extraction solvent, the mixing ratio can be adjusted appropriately. For example, when a mixture of water and a lower aliphatic alcohol is used as an extraction solvent, the mixing ratio of water to lower aliphatic alcohol is preferably 9:1 to 1:9 (volume ratio), more preferably 7:3 to 2:8 (volume ratio). When a mixture of water and a lower aliphatic ketone is used, the mixing ratio of water to lower aliphatic ketone is preferably 9:1 to 2:8 (volume ratio), and when a mixture of water and a polyhydric alcohol is used, the mixing ratio of water to polyhydric alcohol is preferably 5:5 to 1:9 (volume ratio).

[0041] The extraction process is not particularly limited as long as the soluble components contained in the extraction raw material can be dissolved in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in an extraction solvent of 5 to 15 times the amount (mass ratio) of the extraction raw material, and the soluble components are extracted at room temperature or under reflux heating, and then the extraction residue is removed by filtration to obtain an extract. The solvent is distilled off from the obtained extract to obtain a paste-like concentrate, and the concentrate is further dried to obtain a dry product.

[0042] Process (b) Step (b) is a step of adsorbing the sweet tea extract obtained in step (a) onto an adsorbent and then eluting it with water, a water-soluble solvent, or a mixture of these. Step (b) is a step of purifying the sweet tea extract obtained in step (a) for the purposes of increasing the ellagitannin content and decolorizing, deodorizing, improving activity, etc.

[0043] The hydrophilic organic solvent that may be contained in the sweet tea extract is removed by distillation as necessary before being adsorbed by the adsorbent. The extract from which the hydrophilic organic solvent has been removed is dissolved or suspended in, for example, water, a water-soluble solvent, or a mixture thereof, and then adsorbed by the adsorbent. After the sweet tea extract is adsorbed by the adsorbent, it is eluted in water, a water-soluble solvent, or a mixture thereof.

[0044] Examples of water-soluble solvents that can be used for dissolving, suspending, or eluting include the above-mentioned hydrophilic organic solvents, but it is preferable to use the above-mentioned lower alcohols having 1 to 5 carbon atoms, especially methanol, ethanol, etc., as the dissolving solution, suspension, or eluting solution. When using a mixed solvent of water and a water-soluble solvent, the mixing ratio can be appropriately adjusted. For example, when using a mixed solvent of water and ethanol, the mixing ratio of water to ethanol can be 90:10 to 1:99 (volume ratio), preferably 80:20 to 20:80 (volume ratio).

[0045] The adsorbent is not particularly limited as long as it can adsorb ellagitannins, but known adsorbents such as ion exchange resins, synthetic adsorption resins, activated carbon, chelating resins, silica gel, alumina gel-based adsorbents, porous glass, etc. can be used alone or in combination. Preferably, a porous synthetic adsorbent such as Diaion HP-20 (manufactured by Mitsubishi Chemical Corporation), which is a porous synthetic adsorption resin, is used, and the sweet tea extract is subjected to column chromatography using the porous synthetic adsorbent as a packing material, and eluted with an eluent.

[0046] Process (c) Step (c) is a step of subjecting the eluate obtained in step (b) to various types of chromatography to isolate branbuliins A to D contained in the eluate.

[0047] Branbulyins A to D can be isolated from the eluate by combining various chromatographic treatments, such as reverse phase column chromatography, normal phase column chromatography, gel permeation chromatography (GPC), high performance liquid chromatography (HPLC), etc. The order of the chromatographic treatments of the eluate is not particularly limited.

[0048] As the developing solvent or mobile phase in various chromatographies, water, a water-soluble solvent, a low polarity solvent, or a mixed solvent thereof, or a non-polar solvent can be used. As the water-soluble solvent, the above-mentioned hydrophilic organic solvent, acetonitrile, etc. can be used, but it is preferable to use the above-mentioned lower alcohol or lower aliphatic ketone having 1 to 5 carbon atoms, among which, in particular, methanol, ethanol, acetone, etc. In addition, in normal phase column chromatography, it is preferable to use a mixed solvent of chloroform, water, and methanol, a non-polar solvent such as n-hexane, etc. as the mobile phase.

[0049] Examples of packing materials that can be used in various types of chromatography include octadecylated silica gel (ODS), phenylated silica gel, silica gel, hydroxypropylated dextran, polyvinyl alcohol (PVA) polymers, etc. In reversed-phase column chromatography, it is preferable to use ODS or phenylated silica gel, in normal-phase column chromatography, it is preferable to use silica gel, and in gel permeation chromatography (GPC), it is preferable to use hydroxypropylated dextran or PVA polymers.

[0050] By fractionating the fraction containing branbuline A to D using various types of chromatography, purified branbuline A to D can be obtained.

[0051] [Other active ingredients] In this embodiment, the ingredients used as active ingredients other than the above-mentioned branbulyins A to D are 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, and sweet tea extract.

[0052] 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorboyl (α / β)-glucose is an ellagitannin having the chemical structure represented by the following formula (II).

[0053] [ka]

[0054] Rubusuaviin A is an ellagitannin having the chemical structure represented by formula (III):

[0055] [ka]

[0056] Brevifolincarboxylic acid is a gallic acid derivative having the chemical structure represented by formula (IV):

[0057] [ka]

[0058] Isostrictinin, also known as sanguiin H-5, is an ellagitannin having the chemical structure represented by the following formula (V).

[0059] [ka]

[0060] Rubusoside is a steviol glycoside having the chemical structure represented by formula (VI):

[0061] [ka]

[0062] Ellagic acid is a polyphenol having the chemical structure represented by formula (VII):

[0063] [ka]

[0064] 2,3-O-Hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, and ellagic acid can be produced by synthesis, or by isolating and purifying from extracts of plants containing these compounds. Examples of such plant extracts include the following sweet tea extract.

[0065] The sweet tea extract is an extract obtained by using sweet tea (scientific name: Rubus suavissimus) as an extraction raw material. Here, the "sweet tea extract" used as an active ingredient in this embodiment includes an extract obtained by using sweet tea as an extraction raw material, a diluted solution or concentrated solution of the extract, a dried product obtained by drying the extract, or any of the crude or purified products thereof.

[0066] The sweet tea extract can be obtained, for example, as an extract, a diluted or concentrated solution of the extract, or a dried product obtained by drying the extract, by the step (a) described above as a process for producing Branbriins A to D. Furthermore, it may be further subjected to the step (b) or (c) to obtain a crude or purified product.

[0067] When 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, and ellagic acid are isolated and purified from the extract obtained as above, the concentrate of the extract, or the dried product of the extract, the method is not particularly limited and can be performed by a conventional method. Specific examples of the method include the steps (b) and (c) described above as the manufacturing process for brambilins A to D.

[0068] [Aquaporin 5 mRNA expression promoter, aquaporin 3 mRNA expression promoter, plaque formation inhibitor, serine palmitoyltransferase mRNA expression promoter] The aquaporin 5 (AQP5) mRNA expression promoter, aquaporin 3 (AQP3) mRNA expression promoter, plaque formation inhibitor, and serine palmitoyltransferase (SPT) mRNA expression promoter of this embodiment contain the above-mentioned bramblyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifoline carboxylic acid, isostrictinine, rubusoside, ellagic acid, or sweet tea extract as an active ingredient. The AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, and SPT mRNA expression promoter of this embodiment can be used for a wide range of applications such as medicines, quasi-drugs, and oral preparations described below.

[0069] In this embodiment, any one of brevifolin A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract may be used as the active ingredient, or two or more of these may be mixed and used as the active ingredient. When branbuline A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract are mixed and used as the above-mentioned active ingredient, the mixing ratio can be appropriately adjusted depending on the degree of AQP5 mRNA expression promoting effect, AQP3 mRNA expression promoting effect, plaque formation inhibitory effect, or SPT mRNA expression promoting effect of branbuline A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract.

[0070] The AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, or SPT mRNA expression promoter of this embodiment may consist solely of branbulyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, and sweet tea extract, as well as mixtures thereof, or may be formulations of these active ingredients.

[0071] The AQP5mRNA expression promoter, AQP3mRNA expression promoter, plaque formation inhibitor, and SPTmRNA expression promoter of the present embodiment can be formulated into any dosage form such as powder, granules, tablets, liquid, etc., using pharma- ceutically acceptable carriers such as dextrin, cyclodextrin, and other optional auxiliary agents according to a conventional method. In this case, examples of auxiliary agents that can be used include excipients, binders, disintegrants, lubricants, stabilizers, flavorings, and odorants. The AQP5mRNA expression promoter, AQP3mRNA expression promoter, plaque formation inhibitor, and SPTmRNA expression promoter can be used by blending them with other compositions (for example, oral preparations, foods and beverages, which will be described later).

[0072] When the AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, or SPT mRNA expression promoter of this embodiment is formulated, the contents of branbuliins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, and sweet tea extract, as well as mixtures thereof, are not particularly limited and can be set appropriately depending on the purpose.

[0073] In addition, the AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, or SPT mRNA expression promoter of this embodiment can be used as an active ingredient by blending, if necessary, other natural extracts having an AQP5 mRNA expression promoting effect, an AQP3 mRNA expression promoting effect, a plaque formation inhibitory effect, or an SPT mRNA expression promoting effect, together with branbuliins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, and sweet tea extract, and mixtures thereof.

[0074] Methods for administering the AQP5mRNA expression promoter, AQP3mRNA expression promoter, plaque formation inhibitor, or SPTmRNA expression promoter of this embodiment to a patient include transdermal administration, oral administration, etc., and a method suitable for prevention, treatment, etc. may be appropriately selected depending on the type of disease. Furthermore, the dosage of the AQP5mRNA expression promoter, AQP3mRNA expression promoter, plaque formation inhibitor, or SPTmRNA expression promoter of this embodiment may be appropriately increased or decreased depending on the type and severity of the disease, individual differences between patients, administration method, administration period, etc.

[0075] The AQP5mRNA expression promoter of this embodiment can promote the secretion of saliva via AQP5 through the AQP5mRNA expression promoting action of the active ingredients bramblyin A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinine, rubusoside, and sweet tea extract, and can prevent, treat, or improve xerostomia, and is particularly effective in improving bad breath caused by dry mouth, for example. In addition, since AQP5 is known to be localized in the apical membrane of the lacrimal gland and contribute to lacrimal gland secretion, the AQP5mRNA expression promoter of this embodiment can promote lacrimal gland secretion and prevent, treat, or improve symptoms involving lacrimal gland secretion, such as dry eye. However, the AQP5mRNA expression promoter of this embodiment can be used for all applications in which it is meaningful to exert the AQP5mRNA expression promoting action in addition to these applications.

[0076] The AQP3mRNA expression promoter of this embodiment can promote the secretion of saliva from salivary gland acinar cells and prevent, treat or improve xerostomia through the AQP3mRNA expression promoting action of the active ingredients brambuline A, isostrictinine, rubusoside and sweet tea extract. In addition, since AQP3 is expressed in epidermal cells of the skin and contributes to moisture retention in the skin, the AQP3mRNA expression promoter of this embodiment can improve moisture retention ability and barrier function due to aging. However, the AQP3mRNA expression promoter of this embodiment can be used for all applications in which it is meaningful to exert the AQP3mRNA expression promoting action in addition to these applications.

[0077] The plaque formation inhibitor of the present embodiment can inhibit plaque formation and prevent, treat or improve dental caries through the plaque formation inhibitory action of the active ingredients brambuline A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A and isostrictinin. However, the plaque formation inhibitor of the present embodiment can be used for all applications in which it is meaningful to exert a plaque formation inhibitory action in addition to these applications.

[0078] The SPTmRNA expression promoter of this embodiment can strengthen the barrier function of the skin through the SPTmRNA expression promoting action of branbuline A, branbuline B, branbuline D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, brevifoline carboxylic acid, isostrictinin, rubusoside, ellagic acid, and sweet tea extract, and can prevent, treat or improve rough skin, dry skin, and dry skin diseases (e.g., atopic dermatitis, psoriasis, ichthyosis, etc.). However, in addition to these uses, the SPTmRNA expression promoter of this embodiment can be used for all uses where it is meaningful to exert an SPTmRNA expression promoting action.

[0079] In addition, brambuline A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifoline carboxylic acid, isostrictinin, rubusoside, and sweet tea extract can be used as active ingredients in oral xerostomia suppressants because they can suppress dry mouth by utilizing their AQP5 mRNA expression-promoting effect or AQP3 mRNA expression-promoting effect, and further, they can be used as active ingredients in oral xerostomia improvers because they can prevent, treat, or improve bad breath through their xerostomia suppressing effect.

[0080] The AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, or SPT mRNA expression promoter of this embodiment has excellent AQP5 mRNA expression promoting effect, AQP3 mRNA expression promoting effect, plaque formation inhibitory effect, or SPT mRNA expression promoting effect, and can therefore be suitably used as reagents for research into the mechanisms of action of these agents.

[0081] [Oral preparations] Branburin A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinine, rubusoside, or sweet tea extract have excellent AQP5mRNA expression promoting action, AQP3mRNA expression promoting action, or plaque formation inhibiting action, and are therefore suitable for incorporation into oral preparations. In this case, branburin A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinine, rubusoside, or sweet tea extract, or a mixture thereof, may be incorporated as is, or an AQP5mRNA expression promoting agent, AQP3mRNA expression promoting agent, or plaque formation inhibiting agent formulated from these components may be incorporated. By incorporating these, it is possible to impart to the oral preparation an effect of promoting AQP5 mRNA expression, an effect of promoting AQP3 mRNA expression, or an effect of inhibiting plaque formation.

[0082] The form of the oral preparation into which brambilins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, or sweet tea extract, or an AQP5 mRNA expression promoter, an AQP3 mRNA expression promoter, or a plaque formation inhibitor may be blended is not particularly limited, and examples include various toothpastes, mouthwashes, lozenges, oral pastas, gum massage creams, mouthwashes, mouth fresheners, etc.

[0083] When brambilins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, or sweet tea extract, or an AQP5 mRNA expression promoter, an AQP3 mRNA expression promoter, or a plaque formation inhibitor is incorporated into an oral preparation, the amount incorporated can be adjusted appropriately depending on the type of oral preparation, but a suitable blending rate is about 0.0001 to 10% by mass, and a particularly suitable blending rate is about 0.001 to 1% by mass when converted to a standard extract.

[0084] The oral preparation of this embodiment can be used in combination with a main ingredient, auxiliary agent, or other ingredient that is used in the manufacture of a normal oral preparation, so long as it does not interfere with the AQP5 mRNA expression promoting effect, AQP3 mRNA expression promoting effect, or plaque formation inhibiting effect of brambilins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, or sweet tea extract, examples of which include calcium hydrogen phosphate, calcium carbonate, insoluble sodium metaphosphate, aluminosilicate, silicic anhydride, and resin; abrasives such as sodium long-chain alkyl sulfate, and lauryl sulfoacetic acid. It is possible to use in combination surfactants such as sodium, lauryl diethanolamide, and sucrose fatty acid esters; binders such as carboxymethylcellulose (CMC), hydroxyethylcellulose, alginates, carrageenan, gum arabic, and polyvinyl alcohol; thickeners such as polyethylene glycol, sorbitol, glycerin, and propylene glycol; sweeteners such as saccharin, steviosides, glycyrrhizic acid, and thaumatin; preservatives such as dehydroacetic acid and sodium dehydroacetate; flavors such as menthol, carvone, eugenol, anethole, peppermint oil, spearmint oil, peppermint oil, eucalyptus oil, ginger oil, and anise oil; and various dyes. By using these in combination, the oral preparation can be made into a more general product.

[0085] In addition, when producing the oral preparation of the present invention, other AQP5mRNA expression promoters, AQP3mRNA expression promoters, or plaque formation inhibitors may be used in combination. In addition, for example, any anti-inflammatory agent, antibacterial agent, deodorant, etc. may be added, and by adding these anti-inflammatory agents, antibacterial agents, deodorants, etc., it is possible to provide an even more excellent oral preparation.

[0086] Examples of the anti-inflammatory agent that can be added include extracts of Acacia Root, Licorice, Uva Ursi, Scutellaria Baicalensis, Chinese Bamboo Root, Bupleurum Root, Hawthorn, Perilla Root, Peony Root, Sophora Root, Apricot Root, Chinese Bamboo Root, Clove, Peach Blossom, Myrrhizum Root, Peony Root, Mulberry Leaf, etc.; azulene, allantoin, ursolic acid, oleanolic acid, glycyrrhizic acid, glycyrrhetinic acid or derivatives thereof; tocopherol, tranexamic acid, etc. Examples of the antibacterial agent that can be added include extracts of Acanthus Root, Acanthus Root, Zanthoxylum Root, Ginger, Dill, Thyme, Rosemary, Oil-soluble Licorice Extract, etc.; ascorbic acid, mutastine, humic acid, linoleic acid, linolenic acid, etc. Further, examples of deodorizing agents that can be added include extracts of amacha, fennel, oak salicylate, cinnamon, pepper, mace, sage, perilla, ginkgo, persimmon leaves, green tea, oolong tea, chili pepper, tamarind husk, etc.; rosin, oyster astringent, actisol, chlorophyllin derivatives, chlorhexidine, Maillard reaction products, etc.

[0087] The oral preparation of this embodiment can prevent, treat or improve xerostomia; prevent, treat or improve bad breath; through the AQP5mRNA expression promoting action or AQP3mRNA expression promoting action of branbulyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, or sweet tea extract. In addition, the oral preparation of this embodiment can inhibit plaque formation and prevent, treat or improve dental caries through the plaque formation inhibitor action of branbulyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, or isostrictinin.

[0088] [Food and beverages] Branbulyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, and sweet tea extract have excellent AQP5 mRNA expression promoting effects, AQP3 mRNA expression promoting effects, plaque formation inhibitory effects, and SPT mRNA expression promoting effects, and are therefore suitable for incorporation into foods and beverages. In this case, brambuline A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract, or a mixture of these, may be blended as is, or an AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, or SPT mRNA expression promoter formulated from these components may be blended.

[0089] Here, the term "food and drink" refers to food and drink that is unlikely to be harmful to human health and is taken orally or by administration through the digestive tract in normal social life, and is not limited to administrative classifications such as food, medicine, and quasi-drug. Therefore, the "food and drink" in this embodiment broadly includes general food, health food, functional food, health functional food (specified health food, functional food, nutrient functional food), quasi-drug, medicine, etc. that are taken orally. The food and drink according to this embodiment is preferably a food and drink that can display the favorable effects of lavender sage extract on the food and drink or its packaging, and is particularly preferably a health functional food (specified health food, functional food, nutrient functional food), quasi-drug, and medicine.

[0090] When brambilins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract, or an AQP5 mRNA expression promoter, an AQP3 mRNA expression promoter, a plaque formation inhibitor, or an SPT mRNA expression promoter are incorporated into food or beverages, the amount of active ingredient incorporated can be changed as appropriate taking into consideration the purpose of use, symptoms, gender, etc., but it is preferable to ensure that the daily intake of the extract for an adult is approximately 1 to 1000 mg, taking into consideration the general intake of the food or beverage to which it is added. In addition, when the food or beverage to which the compound is to be added is in the form of granules, tablets, or capsules, the amount of brambuline A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract, or the AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, or SPT mRNA expression promoter formulated from these components, added is typically 0.1 to 100% by mass, and preferably 5 to 100% by mass, of the food or beverage to which the compound is to be added.

[0091] The food and beverage of this embodiment may be any food or beverage containing brembulyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract that does not interfere with their activity, or may be a nutritional supplement containing these ingredients as the main ingredients.

[0092] When producing the food and beverage products of this embodiment, any auxiliary agent can be added, such as sugars such as dextrin and starch; proteins such as gelatin, soy protein, and corn protein; amino acids such as alanine, glutamine, and isoleucine; polysaccharides such as cellulose and gum arabic; and fats and oils such as soybean oil and medium-chain fatty acid triglycerides, to form the food and beverage products into any shape.

[0093] Foods and beverages that can contain branbulyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract are not particularly limited, and specific examples include confectionery, bread, candy, chewing gum, gummy, jelly, chocolate, tablet candy, soft drinks, and other various forms of health and nutritional supplements, tablets, capsules, drinks, etc. When branbulyins A to D, 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, rubusoside, ellagic acid, or sweet tea extract are contained in these foods and beverages, commonly used auxiliary raw materials and additives can be used in combination.

[0094] The AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor, and SPT mRNA expression promoter, oral preparations, and foods and beverages of this embodiment are preferably applied to humans, but can also be applied to animals other than humans (e.g., mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, etc.) as long as their respective functional effects are achieved. EXAMPLES

[0095] The present invention will be specifically explained below by showing test examples, but the present invention is not limited to the following examples in any way.

[0096] [Production Example] Production of compounds derived from sweet tea 55.5g of hot water extract of sweet tea leaves (Tencha Extract M, Maruzen Pharmaceutical Co., Ltd.) was dissolved in distilled water and fractionated with Diaion HP-20 (Mitsubishi Chemical Co., Ltd.) to obtain unadsorbed part (26g), 20% EtOH elution part (8.5g), 40% EtOH elution part (7.0g), 60% EtOH elution part (2.3g), and MeOH recovery part (11g). Of these, 20% EtOH elution part (8.5g) was fractionated using CHROMATOREX-DIOL silica gel (Fuji Silysia Chemical Co., Ltd.) (mobile phase CHCl3:MeOH=3:1→1:2) to obtain Fr.1 (490mg), Fr.2 (790mg), Fr.3 (1.6g), Fr.4 (2.3g), and Fr.5 (3.6g).

[0097] Fractionation of Fr.3 (1.4 g) was performed using SEPHADEX LH-20 (GE Healthcare) (mobile phase MeOH:H2O = 2:8 → acetone:H2O = 1:1). A portion (750 mg) of the obtained 50% acetone eluted fraction was purified by preparative HPLC (column: Develosil RPAQUEOUS AR-5 (Nomura Chemical), mobile phase MeOH:H2O = 28:72) to isolate purified product a (23 mg, sample 1).

[0098] Fractionation of Fr.5 (3.6 g) was performed using SEPHADEX LH-20 (GE Healthcare) (mobile phase MeOH:H2O = 2:8 → acetone:H2O = 1:1). Of this, the 50% acetone elution fraction (1.4 g) was purified by preparative HPLC (column: Develosil RPAQUEOUS AR-5 (Nomura Chemical), mobile phase MeOH:H2O = 28:72) to obtain purified product b (44 mg, sample 2), purified product c (24 mg, sample 3), and purified product d (16 mg, sample 4).

[0099] The 20% MeOH eluted fraction (270 mg) obtained by fractionating Fraction 3 using SEPHADEX was purified by preparative HPLC (column: Develosil RPAQUEOUS AR-5 (Nomura Chemical Co., Ltd.), mobile phase: MeOH:H2O=20:80) to obtain purified product e (94 mg, sample 5).

[0100] In addition, a portion (210 mg) of the 50% acetone eluted fraction obtained by fractionating Fraction 3 using SEPHADEX was purified by preparative HPLC (column: Develosil RPAQUEOUS AR-5 (Nomura Chemical Co., Ltd.), mobile phase: MeOH:HO=25:75) to obtain purified product f (14 mg, sample 6).

[0101] Fraction 2 (760 mg) fractionated with CHROMATOREX-DIOL silica was further fractionated using Toyopearl HW-40 (Tosoh Corporation) (mobile phase MeOH:H2O = 2:8 → acetone:H2O = 1:1). Of this, the 20% MeOH elution fraction (100 mg) was purified by preparative HPLC (column: Develosil RPAQUEOUS AR-5 (Nomura Chemical Co., Ltd.), mobile phase MeOH:H2O = 35:65) to obtain purified product g (47 mg, sample 7).

[0102] In addition, the 50% acetone eluted fraction (130 mg) obtained by fractionation with Toyopearl was purified by preparative HPLC (column: Develosil RPAQUEOUS AR-5 (Nomura Chemical Co., Ltd.), mobile phase MeOH:HO=20:80) to obtain purified product h (33 mg, sample 8).

[0103] The MeOH recovery fraction (11 g) fractionated with the above-mentioned HP-20 was fractionated successively with CHROMATOREX-ODS (manufactured by Fuji Silysia Chemical) (mobile phase MeOH:HO=6:4) and silica gel 60N (manufactured by Kanto Chemical) (mobile phase CHCl3:MeOH:HO=10:5:1), and then recrystallized from methanol to obtain purified product i (2.4 g, sample 9).

[0104] Regarding the purified products a to i obtained as described above, 13 C-NMR analysis, 1 H-NMR analysis, mass spectrometry, etc. were performed, and the obtained values ​​were compared with the literature values.

[0105] Purified product a <マススペクトル> m / z:1265(M-H) - m / z:1265.1356(M-H) - (HR-MS) < 13 C-NMR(methanol-d4)δ C > 61.89(glc-6’-C),64.0(glc-6-C),67.9(glc-4’-C),73.4(glc-5-C),73.6(glc-4-C),74.5(glc-2-C),76.1(glc-2’-C),76.3(glc-3-C),79.4(glc-5’-C),81.0(glc-3’-C),92.9(glc-1’-C),96.1(glc-1-C),107.7(HHDP-3-C),107.9(HHDP-3’-C),108.5(sang-3-C),110.4(galloyl-2,6-C,sang-6’’-C),110.6(sang-2’’-C),112.1(HHDP-1-C),115.4(HHDP-1’-C),115.4(sang-1-C),116.3(sang-1’-C),116.5(galloyl-1-C),120.0(sang-2’-C),120.3(sang-1’’-C),121.0(HHDP-2-C),126.0(HHDP-2’-C),126.2(sang-2-C),126.8(sang-3’-C),135.6(HHDP-5-C),137.3(HHDP-5’-C),137.4(sang-5-C),137.5(sang-5’-C),138.9(sang-4’-C),139.7(galloyl-4-C),140.5(sang-4’’-C),141.0(sang-6’-C),142.6(HHDP-6-C),144.7(sang-6-C),145.2(HHDP-4-C),145.7(HHDP-4’-C),145.9(HHDP-6’-C),146.0(sang-4-C),146.5(galloyl-3,5-C),146.8(sang-5’’-C),149.2(sang-3’’-C),166.2(galloyl-7-C),167.0(sang-7’-C),167.6(sang-7-C),169.5(HHDP-7’-C),170.1(sang-7’’-C),171.1(HHDP-7-C)

[0106] < 1 H-NMR(methanol-d4)δ> 3.24(1H,t,J=8.5 Hz,glc-3-H),3.36(1H,t,J=8.5 Hz,glc-2-H),3.48(1H,dd,J=10.1,6.2Hz,glc-5-H),3.59(1H,m,glc-5'-H),3.68(1H,m,glc- 6-H),3.73(1H,m,glc-6'-H),3.76(1H,m,glc-4'-H),3.80(1H,m,glc-6'-H),4.60(1H,t,J=9.5 Hz,glc-4-H),5.09(1H,dd,J=9.5,8.5 Hz,glc-2'-H),5.16(1H,dd,J=10.1,6.2 Hz,glc-3'-H),5.21(1H,dd,J=13.3,6.2 Hz,glc-6-H),5.39(1H,d,J=8.0 Hz,glc-1-H),6.09(1H,d,J=8.5 Hz,glc-1'-H),6.43(1H,s,HHDP-3'-H),6.51(1H,s,HHDP-3-H),6.65(1H,s,sang-3-H),7.00(1H,d,J=2.0 Hz,sang-2''-H),7.09(2H,s,galloyl-2,6-H),7.25(1H,d,J=2.0 Hz,sang-6''-H)

[0107] From the above analysis results, the purified product a obtained from the sweet tea extract was confirmed to be a novel ellagitannin represented by the following formula (I-1). This novel compound was named brambliin A.

[0108] [ka]

[0109] Purified product b <Mass spectrum> m / z: 1567(MH) - m / z: 1567.1427(MH) - (HR-MS)

[0110] < 13 C-NMR (acetone-d6+D2O) 60.7(glc-6’-C),62.3(glc-6-C),66.7(glc-4’-C),68.6(glc-3-C),73.1(glc-5-C),74.8(glc-2’-C),75.1(glc-2-C),75.8(glc-4-C),77.8(glc-5’-C),79.5(glc-3’-C),91.5(glc-1,1’-C),106.5[HHDP(glc-2)-3-C],106.6[HHDP(glc-2’)-3-C],106.7[HHDP(glc-3’)-3’-C],107.3[HHDP(glc-3)-3’-C],107.5[sang(glc-6)-3-C],109.6[sang(glc-1’)-2’’-C,galloyl-2,6-C],111.7[sang(glc-1’)-6’’-C],113.7[HHDP(glc-3)-1’-C],113.8[HHDP(glc-3’)-1’-C],114.3[HHDP(glc-2’)-1-C,HHDP(glc-2)-1-C],114.7[sang(glc-4)-1’-C,sang(glc-6)-1-C],118.5[galloyl-1-C,sang(glc-1’)-1’’-C],120.0[sang(glc-4)-2’-C],124.6[HHDP(glc-2)-2-C],125.0[HHDP(glc-2’)-2-C],125.2[HHDP(glc-3)-2’-C],125.3[HHDP(glc-3’)-2’-C],125.9[sang(glc-6)-2-C],134.5[sang(glc-4)-3’-C],135.5[HHDP(glc-3’)-5’-C],135.6[HHDP(glc-3)-5’-C],135.7[HHDP(glc-2’)-5-C],135.8[HHDP(glc-2)-5-C],135.9[sang(glc-6)-5-C],137.3[sang(glc-4)-5’-C],137.6[sang(glc-4)-4’-C],139.5(galloyl-4-C),140.5[sang(glc-1’)-4’’-C],141.4[sang(glc-4)-6’-C],143.4[HHDP(glc-2)-6-C],143.6[HHDP(glc-2’)-6-C],143.7[sang(glc-6)-6-C],144.2[HHDP(glc-3)-4’-C],144.3[HHDP(glc-2’)-4-C],144.4[HHDP(glc-3)-6’-C,HHDP(glc-2)-4-C],144.5[HHDP(glc-3’)-6’-C,HHDP(glc-3’)-4’-C],144.8[sang(glc-6)-4-C],145.3[sang(glc-1’)-5’’-C],145.5(galloyl-3,5-C),147.4[sang(glc-1’)-3’’-C],164.8[sang(glc-1’)-7’’-C],165.0(galloyl-7-C),165.7[sang(glc-4)-7’-C],167.6[HHDP(glc-3)-7’-C],167.8[sang(glc-6)-7-C],168.1[HHDP(glc-2)-7-C],168.3[HHDP(glc-2’)-7-C],169.2[HHDP(glc-3’)-7’-C].

[0111] < 1 H-NMR(acetone-d6+D2O)> 3.68(1H,m,glc-5'-H),3.74(1H,dd,J=13.5,5.1 Hz,glc-6'-H),3.81(1H,t,J=9.0 Hz,glc-4'-H),3.89(2H,brd,J=13.5 Hz,glc-6,6'-H),3.91(1H,m,glc-5-H),4.90(1H,m,glc-3-H)4.94(1H,m,glc-4-H),4.99(1H,t,J=9.0 Hz,glc-2'-H),5.04(1H,t,J=8.6 Hz,glc-2-H),5.13(1H,t,J=9.0 Hz,glc-3'-H),5.56(1H,dd,J=13.5,6.2 Hz,glc-6-H),5.99(1H,d,J=8.6 Hz,glc-1-H),6.07(1H,d,J=9.0 Hz,glc-1'-H),6.18(1H,s,HHDP(glc-3)-3'-H),6.32(1H,s,HHDP(glc-2)-3-H),6.45(1H,s,HHDP( glc-2')-3-H),6.66(1H,s,HHDP(glc-3')-3'-H),6.70(1H,s,sang(glc-6)-3-H),7.01(1H,d,J=1.8 Hz,sang(glc-1')-2''-H),7.05(1H,d,J=1.8 Hz,sang(glc-1')-6''-H),7.09(2H,s,galloyl-2,6-H)

[0112] From the above analysis results, the purified product b obtained from the sweet tea extract was confirmed to be a novel ellagitannin represented by the following formula (I-2). This novel compound was named brambliin B.

[0113] [ka]

[0114] Purified product c <Mass spectrum> m / z: 1567(MH) - m / z: 1567.1436(MH) - (HR-MS)

[0115] < 13 C-NMR(methanol-d4)> 62.5(glc-6-C),63.2(glc-6’-C),68.3(glc-4-C),72.0(glc-4’-C),72.5(glc-5’-C),72.7(glc-2’-C),72.9(glc-5-C),74.5(glc-3’-C),74.5(glc-2-C),76.1(glc-3-C),91.3(glc-1-C),95.0(glc-1’-C),106.2[HHDP(glc-3)-3’-C],106.8[HHDP(glc-6’)-3-C],107.0[HHDP(glc-4’)-3’-C],107.3[HHDP(glc-2)-3-C],107.6[sang(glc-6)-3-C],109.1(galloyl-2,6-C),110.4[sang(glc-1’)-2’’-C],111.7[sang(glc-1’)-6’’-C],113.9[HHDP(glc-4’)-1’-C],114.1[HHDP(glc-3)-1’-C,HHDP(glc-4’)-1’-C],114.4[sang(glc-4)-1’-C],114.5[sang(glc-6)-1-C],115.0[HHDP(glc-6’)-1-C],115.6[HHDP(glc-2)-1-C],117.9[sang(glc-6)-2-C],118.3(galloyl-1-C),120.0[sang(glc-1’)-1’’-C],124.4[sang(glc-4)-2’-C],124.6[HHDP(glc-2)-2-C],124.8[HHDP(glc-6’)-2-C],124.9[HHDP(glc-3)-2’-C],125.7[HHDP(glc-4’)-2’-C],134.9[sang(glc-4)-3’-C],135.8[HHDP(glc-6’)-5-C],136.0[sang(glc-4)-5’-C],136.1[HHDP(glc-3)-5’-C,HHDP(glc-4’)-5’-C],136.2[sang(glc-6)-5-C],136.4[HHDP(glc-2)-5-C],137.6[sang(glc-4)-4’-C],137.8[sang(glc-4)-6’-C],139.3[HHDP(glc-2)-6-C],140.9[sang(glc-1’)-4’’-C],141.0[galloyl-4-C],143.1[HHDP(glc-6’)-6-C],143.4[sang(glc-6)-6-C],144.1[HHDP(glc-4’)-4’-C],144.3[HHDP(glc-6’)-4-C],144.4[HHDP(glc-4’)-6’-C,HHDP(glc-3)-4’-C],144.6[HHDP(glc-3)-6’-C,HHDP(glc-2)-4-C],144.8[sang(glc-6)-4-C],145.2(galloyl-3,5-C),145.5[sang(glc-1’)-5’’-C],147.0[sang(glc-1’)-3’’-C],164.5[galloyl-7-C],165.5[sang(glc-4)-7’-C],165.6[sang(glc-1’)-7’’-C],167.8[sang(glc-6)-7-C],168.0[HHDP(glc-4’)-7’-C],168.3[HHDP(glc-2)-7-C],168.6[HHDP(glc-3)-7’-C],168.7[HHDP(glc-6’)-7-C].

[0116] < 1 H-NMR(methanol-d4)> 3.70(1H,t,J=9.0 Hz,glc-3'-H),3.85(1H,t,J=9.0 Hz,glc-2'-H),3.93(1H,dd,J=9.3,6.8 Hz,glc-5-H),4.01(2H,brd like,J=13.4 Hz,glc-6,6'-H),4.04(1H,dd,J=9.0,6.3 Hz,glc-5'-H),4.62(1H,t,J=9.3 Hz,glc-3-H),4.84(1H,m,glc-4-H),5.02(1H,t,J=9.3 Hz,glc-4-H),5.09(1H,t,J=9.3 Hz,glc-2-H),5.15(1H,dd,J=13.4,6.3 Hz,glc-6'-H),5.74(1H,dd,J=13.4,6.8 Hz,glc-6-H),5.75(1H,d,J=9.3 Hz,glc-1-H),5.79(1H,d,J=9.0 Hz,glc-1'-H),6.32[1H,s,HHDP(glc-3)-3'-H],6.40[1H,s,HHDP(glc-4')-3'-H],6.45[1H,s,HHDP(glc-6')-3-H],6.68[1H,s,HHDP(glc-2 )-3-H],6.73[1H,s,sang(glc-6)-3-H],6.98(2H,s,galloyl-2,6-H),7.23[1H,s,sang(glc-1')-2''-H],7.27[1H,s,sang(glc-1')-6''-H]

[0117] From the above analysis results, the purified product c obtained from the sweet tea extract was confirmed to be a novel ellagitannin represented by the following formula (I-3). This novel compound was named brambliin C.

[0118] [ka]

[0119] Purified product d <Mass spectrum> m / z: 2037(MH) - m / z: 2037.1512(MH) -(HR-MS)

[0120] < 13 C-NMR(methanol-d4)> 62.3(glc-6-C,glc-6’-C),68.6(glc-4-C,glc-4’-C),73.1(glc-5’-C),73.3(glc-5-C),74.7(glc-2-C),74.8(glc-2’-C),76.0(glc-3-C,glc-3’-C),91.3(glc-1-C),91.5(glc-1’-C),106.2[HHDP(glc-2)-3-C],106.5[HHDP(glc-2’)-3-C],107.2[HHDP(glc-3)-3’-C,HHDP(glc-3’)-3’-C,sang(glc-6)-3-C],107.5[sang(glc-6’)-3-C],108.3(sang-2’’-C),109.1[sang(glc-1’)-2’’-C,galloyl-2,6-C],111.2(sang-6’’-C),111.5[sang(glc-1’)-6’’-C],113.8[HHDP(glc-2)-1-C],114.2[HHDP(glc-3’)-1’-C],114.3[HHDP(glc-3)-1’-C,HHDP(glc-2’)-1-C],114.7[sang(glc-6)-1-C,sang-(glc-6’)-1-C],115.3[sang(glc-4)-1’-C,sang(glc-4’)-1’-C],117.6[sang(glc-6)-2-C,sang(glc-6’)-2-C],118.3[sang(glc-4)-2’-C,sang(glc-4’)-2’-C,galloyl-1-C],119.8[sang(glc-1’)-1’’-C],120.4(sang-1’’-C),124.5[HHDP(glc-2’)-2-C],124.6[HHDP(glc-2)-2-C],124.7[HHDP(glc-3)-2’-C],124.8[HHDP(glc-3’)-2’-C],134.0[sang(glc-4’)-3’-C],134.6[sang(glc-4)-3’-C],136.0[HHDP(glc-2)-5-C,HHDP(glc-2’)-5-C],136.2[HHDP(glc-3)-5’-C,sang(glc-6)-5-C],137.6[HHDP(glc-3’)-5’-C],137.8[sang(glc-6’)-5-C],138.1[sang(glc-4)-5’-C,sang(glc-4’)-5’-C],138.9[sang(glc-4’)-4’-C],139.4[sang(glc-4)-4’-C],140.8(galloyl-4-C,sang-4’’-C),141.1[sang(glc-1’)-4’’-C],141.4[sang(glc-4’)-6’-C],143.0[sang(glc-4)-6’-C],143.1[HHDP(glc-2’)-6-C],143.3[HHDP(glc-2)-6-C],143.4[sang(glc-6’)-6-C],144.0[sang(glc-6)-6-C],144.1[HHDP(glc-3)-4’-C],144.2[HHDP(glc-3’)-4’-C],144.3[HHDP(glc-3)-6’-C,HHDP(glc-2)-4-C],144.7[HHDP(glc-3’)-6’-C,HHDP(glc-2’)-4-C],144.8[sang(glc-6)-4-C,sang(glc-6’)-4-C],145.1(sang-5’’-C),145.3(galloyl-3,5-C),145.5[sang(glc-1’)-5’’-C],147.1(sang-3’’-C),147.2[sang(glc-1’)-3’’-C],164.7[galloyl-7-C,sang(glc-1’)-7’’-C],165.7[sang(glc-3)-7’-C,sang(glc-3’)-7’-C,sang(glc-4)-7’-C,sang(glc-4’)-7’-C],167.8[sang(glc-6’)-7-C],167.9[sang(glc-6)-7-C],168.2[HHDP(glc-2’)-7-C],168.6[HHDP(glc-2)-7-C],169.3(sang-7’’-C).

[0121] < 1 H-NMR(methanol-d4)> 3.79(1H,m,glc-5-H),3.86(1H,m,glc-5'-H),3.93(2H,dd,J=13.0,6.0 Hz,glc-6,6'-H),4.89(3H,m,glc-3,3',4,-H),4.96(1H,m,glc-4'-H),5.07(1H,t,J=8.7 Hz,glc-2-H),5.13(1H,t,J=8.4 Hz,glc-2'-H),5.39(1H,dd,J=13.0,6.0 Hz,glc-6-H),5.55(1H,dd,J=13.0,6.0 Hz,glc-6'-H),5.85(1H,d,J=8.7 Hz,glc-1-H),5.95(1H,d,J=8.4 Hz,glc-1'-H),6.15[1H,s,HHDP(glc-3)-3'-H],6.29[1H,s,HHDP(glc-3')-3'-H],6.32[1H,s,HHDP(glc-2)-3-H], 6.35[1H,s,HHDP(glc-2')-3-H],6.63[1H,s,sang(glc-6)-3-H],6.71[1H,s,sang(glc-6')-3-H],6.92(1H,d,J=1.7 Hz,sang-2''-H),7.20(2H,s,galloyl-2,6-H),7.07[1H,s,sang(glc-1')-2''-H],7.09(1H,d,J=1.7 Hz,sang-6''-H),7.15[1H,s,sang(glc-1')-6''-H]

[0122] From the above analysis results, the purified product d obtained from the sweet tea extract was confirmed to be a novel ellagitannin represented by the following formula (I-4). This novel compound was named brambliin D.

[0123] [ka]

[0124] Purified product e <Mass spectrum> m / z:951(MH) -

[0125] <13 C-NMR(acetone-d6+D2O)δ C > 62.7(glc-6α-C,glc-6β-C),66.8(glc-5α-C),69.1(glc-4α-C),69.6(glc-4β-C),72.1(glc-5β-C),74.5(glc-2α-C),74.8(glc-3β-C),76.3(glc-3α-C),77.2(glc-2β-C),90.7(glc-1α-C),94.5(glc-1β-C),106.4(HHDP-3α-C),106.9(HHDP-3'α-C,HHDP-3'β-C),107.1(sang-3α,β-C),107.3(HHDP -3β-C),109.4(sang-1'α,6''α-C),109.8(sang-1'β,6''β-C),111.1(sang-2''α-C),111.2(sang-2''β-C),113.6(sang-1β-C),114.1(sang-1α-C),114.5(HHDP-1α-C),114.6(HHDP-1β-C),120.2(sang-2'α,2'β-C),120.3(sang-6'α-C),120.5(sang-6'β-C),125.2(sang-2α-C),125.3(sang-2β-C ),125.8(HHDP-1'β-C),125.8(HHDP-1'α-C),125.9(HHDP-2α,2'α-C),126.0(HHDP-2β,2'β-C),134.4(HHDP-5α-C),134.6(HHDP-5β-C),135.5(HHDP-5'α,5'β-C),135.6(sang-3'β,5β-C),136.1(sang-3'α,5α-C),137.8(sang-5'α,5'β-C),139.1(sang-4'α-C),139.3(sang-4'β-C),141.3(sang-1' 'α-C),143.1(sang-1''β-C),143.2(HHDP-3'α-C),143.3(HHDP-3'β-C),144.1(HHDP-3α,3β-C),144.1(sang-6β,6β-C),144.7(sang-4α,4β-C),145.2(sang-5'α,5'β-C),145.3(sang-5''α,5''β-C),147.2(sang-3''α,3''β-C)165.3(sang-7'α-C),165.4(sang-7'β-C),167.2(sang-7α,7β-C),167.4(HHDP-7'α,7'β-C),167.5(sang-7''α,7''β-C),168.0(HHDP-7α-C),168.2(HHDP-7β-C).

[0126] < 1 H-NMR(acetone-d6+DO)δ> 3.65(dd,J=10.2,6.3,glc-5β-H),3.67(brd,J=12.9,glc-6β-H),3.75(brd,J=12.9,glc-6α-H),4.15(dd,J=9.4,6.4 Hz,glc-5α-H),4.67(m,glc-2β-H),4.69(m,glc-3β-H),4.71(m,glc-1β-H),4.76(t,J=9.4 Hz,glc-4α-H),4.78(t,J=10.2 Hz,glc-4β-H),4.89(dd,J=9.4,3.6 Hz,glc-2α-H),4.93(t,J=9.4 Hz,glc-3α-H),5.28(d,J=3.6 Hz,glc-1α-H),5.42(dd,J=12.9,6.4 Hz,glc-6β-H),5.48(dd,J=12.9,6.3 Hz,glc-6α-H),6.30(1H in total,s,sang-3-H),6.46,6.47(1H in total,each s,HHDP-3'-H),6.67,6.69(1H in total,each s,HHDP-3-H),7.06,7.08(1H in total,each d,J=1.8 Hz,sang-6''-H),7.12,7.13(1H in total,each d,J=1.8 Hz,sang-2''-H)

[0127] The above analytical results were compared with the literature values ​​(Hussein SAM et al., Phytochemistry, 63, 905-911 (2003)), and the refined product e obtained from the sweet tea extract was confirmed to be 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorboyl (α / β)-glucose represented by the following formula (II).

[0128]

Chem.

[0129] Purified product f <Mass spectrum> m / z: 1103 (M-H) -

[0130] < 13 C-NMR (acetone-d6 + D2O) δ C > 62.2(glc-6-C),68.6(glc-3-C),73.1(glc-5-C),74.9(glc-2-C),75.9(glc-4-C),91.3(glc-1-C),106.4(HHDP-3-C),107.2(HHDP-3’-C,sang-3-C),109.4(galloyl-2,6-C),109.6(sang-6’’-C),111.2(sang-2’’-C),113.8(HHDP-1-C),114.3(HHDP-1’-C),114.6(sang-1-C),114.7(sang-1’-C),118.5(galloyl-1-C),120.1(sang-2’-C),120.4(sang-1’’-C),124.7(HHDP-2-C),125.0(HHDP-2’-C),125.2(sang-2-C),134.7(sang-3’-C),135.6(HHDP-5-C),135.8(HHDP-5’-C),135.9(sang-5-C),137.2(sang-5’-C),137.8(sang-4’-C),139.2(galloyl-4-C),139.4(sang-4’’-C),141.4(sang-6’-C),143.4(HHDP-6-C),143.6(sang-6-C),144.2(HHDP-4-C),144.3(HHDP-4’-C),144.8(HHDP-6’-C),145.2(sang-4-C),145.5(galloyl-3,5-C,sang-5’’-C),147.2(sang-3’’-C),164.5(galloyl-7-C),165.6(sang-7’-C),167.5(sang-7-C),167.7(HHDP-7’-C),168.1(sang-7’’-C,HHDP-7-C)

[0131] < 1 H-NMR(acetone-d6+D2O)δ> 3.82(1H,m,glc-6-H),3.94(1H,m,glc-5-H),4.85(1H,m,glc-3-H),4.86(1H,m,glc-4-H),5.01(1H,t,J=8.5,glc-2-H),5.50(1H,dd,J=13.4,6.4 Hz,glc-6-H),5.89(1H,d,J=8.5 Hz,glc-1-H),6.28(1H,s,HHDP-3'-H),6.30(1H,s,HHDP-3-H),6.67(1H,s,sang-3-H),7.03(1H,d,J=1.9 Hz,sang-2''-H),7.07(2H,s,galloyl-2,6-H),7.10(1H,d,J=1.9 Hz,sang-6''-H)

[0132] The above analytical results were compared with the literature values ​​(Li H et al., Chem. Pharm. Bull., 55, 1325-1331 (2007)), and it was confirmed that the purified product f obtained from the sweet tea extract was rubusuaviin A represented by the following formula (III).

[0133] [ka]

[0134] Purified product g < 13 C-NMR(acetone-d6+D2O)δ C > 37.8(4-C),41.7(5-C),109.0(3'-C),114.1(1'-C),115.7(2'-C),140.5(3,5'-C) ,143.8(6'-C),146.3(4'-C),150.0(2-C),161.9(7'-C),175.2(6-C),195.5(1-C)

[0135] < 1 H-NMR(acetone-d6+DO)δ> 2.47(1H,brd,J=19.1 Hz,5-H),3.00(1H,dd,J=19.1,6.5 Hz,5-H),7.26(1H,s,3'-H)

[0136] The above analytical results were compared with literature values ​​(Saijo R et al., Chem. Pharm. Bull., 37, 2624-2630 (1989)), and it was confirmed that the purified product g obtained from the sweet tea extract was brevifolincarboxylic acid represented by the following formula (IV).

[0137] [ka]

[0138] Purified product h < 13 C-NMR(methanol-d4)δ C > 60.4(glc-6-C),66.6(glc-4-C),74.6(glc-2-C),78.1(glc-5-C),79.6(glc-3-C),91.3(glc-1-C),106.1(HHDP-3'-C),10 6.6(HHDP-3-C),109.0(galloyl-2,6-C),114.0(HHDP-1-C),114.1(HHDP-1'-C),118.6(galloyl-1-C),124.9(HHDP-2-C), 125.4(HHDP-2'-C),136.0(HHDP-5'-C),136.1(HHDP-5-C),139.3(galloyl-4-C),143.4(HHDP-4'-C),143.5(HHDP-4-C),1 44.5 (HHDP-6-C), 144.6 (HHDP-4'-C), 145.3 (galloyl-3,5-C), 164.9 (galloyl-7-C), 168.8 (HHDP-7'-C), 169.8 (HHDP-7-C)

[0139] < 1 H-NMR(methanol-d4)δ> 3.63(1H,m,glc-5-H),3.78(1H,m,glc-6-H),3.83(1H,m,glc-4-H),3.90(1H,dd,J=12.1,2.4 Hz,glc-6-H),5.06(1H,dd,J=9.6,8.5 Hz,glc-2-H),5.18(1H,t,J=9.6 Hz,glc-3-H),6.07(1H,d,J=8.5 Hz,glc-1-H),6.39(1H,s,HHDP-3'-H),6.68(1H,s,HHDP-3-H),7.08(1H,s,galloyl-2,6-H)

[0140] The above analytical results were compared with literature values ​​(Latte KP et al., Phytochemistry, 54, 701-708 (2000)), and it was confirmed that the purified product h obtained from the sweet tea extract was isostrictinin represented by the following formula (V).

[0141] [ka]

[0142] Purified product i < 13 C-NMR(pyridine-d5)δ C > 15.4(20-C),19.3(2-C),20.5(11-C),22.0(6-C),28.2(18-C),37.1(12-C),38.1(3-C),39.6(10-C),40 .5(1-C),41.5(7-C),42.2(8-C),43.8(4-C),44.3(14-C),47.6(15-C),53.7(9-C),57.1(5-C),61.8(6'' -C),62.9(6'-C),70.8(4''-C),72.2(4'-C),73.8(2''-C),75.3(2'-C),77.9(5'-C),78.6(3''-C),78.9 (3'-C),79.2(5''-C),85.8(13-C),95.7(1'-C),99.6(1''-C),104.3(17-C),154.4(16-C),176.8(19-C)

[0143] < 1 H-NMR(pyridine-d5)δ> 1.24(3H,s,18-H),1.24(3H,s,20-H),4.98(1H,brs,17-H),5.50(1H,brs,17-H),5.09(1H,d,J=7.8 Hz,glc-1'-H),6.10(1H,d,7.7 Hz,glc-1-H)

[0144] The above analytical results were compared with literature values ​​(Tanaka T, et al., Agric. Biol. Chem., 45, 2165-2166 (1981)), and it was confirmed that the purified product i obtained from the sweet tea extract was rubusoside represented by the following formula (VI).

[0145] [ka]

[0146] In addition to the samples 1 to 9 obtained above, ellagic acid (manufactured by Wako Pure Chemical Industries, Ltd., sample 10) and sweet tea extract (manufactured by Maruzen Pharmaceutical Co., Ltd., sweet tea extract M, sample 11) were used in the test examples shown below.

[0147] [Test Example 1] Aquaporin 5 (AQP5) mRNA expression promoting effect test The AQP5 mRNA expression promoting effect of branbuline A (sample 1), branbuline B (sample 2), branbuline C (sample 3), branbuline D (sample 4), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose (sample 5), rubusaviin A (sample 6), brevifolin carboxylic acid (sample 7), isostrictinin (sample 8), and rubusoside (sample 9) obtained in the manufacturing examples, as well as sweet tea extract (sample 11), was tested as follows.

[0148] Mouse alveolar epithelial cells (MLE-12) were cultured at 80 cm 2The cells were pre-cultured in a flask at 37°C and 5% CO2, and then harvested by trypsinization. The harvested cells were 45×10 4 After diluting the cells in DMEM containing 4% FBS to a cell density of 10 cells / mL, 2 mL of the cells were seeded in 35 mm petri dishes (FALCON) (90 × 10 4 The cells were cultured at 37℃ and 5% CO2 for 24 hours.

[0149] After the incubation, the medium was removed, and 2 mL of 4% FBS-containing DMEM medium in which the test samples (samples 1 to 9 and 11, see Table 1 below for sample concentrations) had been dissolved was added to each petri dish, and the cells were incubated for 24 hours at 37°C and 5% CO2. As a control, the cells were incubated in the same manner using 4% FBS-containing DMEM medium without the addition of samples. After the incubation, the medium was removed, and total RNA was extracted using ISOGEN II (Nippon Gene Co., Ltd., Cat. No. 311-07361). The amount of each RNA was measured using a spectrophotometer, and total RNA was adjusted to 200 ng / μL.

[0150] Using this total RNA as a template, the expression levels of mRNA for AQP5 and GAPDH, an internal standard, were measured. Detection was performed by real-time 2-step RT-PCR reaction using a real-time PCR device Smart Cycler (Cepheid) and a TaKaRa SYBR PrimeScript RT-PCR kit (Perfect Real Time) (Takara Bio, code No. RR063A). The expression level of AQP5mRNA was calculated based on the total RNA samples prepared from cells cultured with and without the addition of the test sample, and the correction value was calculated using the GAPDH value. The AQP5mRNA expression promotion rate (%) was calculated from the obtained values ​​using the following formula.

[0151] AQP5 mRNA expression promotion rate (%) = A / B × 100 Each term in the formula represents the following: A: Correction value when test sample is added B: Correction value without sample The results are shown in Table 1.

[0152] [Table 1]

[0153] As shown in Table 1, branbuline A (sample 1), branbuline B (sample 2), branbuline C (sample 3), branbuline D (sample 4), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorboylglucose (sample 5), rubusaviin A (sample 6), brevifoline carboxylic acid (sample 7), isostrictinin (sample 8), rubusoside (sample 9), and sweet tea extract (sample 11) were confirmed to have excellent AQP5 mRNA expression promoting effects.

[0154] [Test Example 2] Aquaporin 3 (AQP3) mRNA expression promoting effect test Branbuliin A (sample 1), isostrictinin (sample 8), and rubusoside (sample 9) obtained in the Production Examples, as well as sweet tea extract (sample 11), were tested for their AQP3 mRNA expression promoting activity as described below.

[0155] Normal human neonatal epidermal keratinocytes (NHEK) were cultured in a growth medium for normal human epidermal keratinocytes (KGM) at 80 cm 2 The cells were pre-cultured in a flask at 37°C and 5% CO2, and then harvested by trypsinization. The harvested cells were diluted to 20 × 10 4 After diluting with KGM medium to a cell density of 10 cells / mL, 2 mL of the cells were seeded (40 × 10 4 The cells were cultured at 37℃ and 5% CO2 for 24 hours.

[0156] After the incubation, the medium was removed, and 2 mL of KGM medium in which the test samples (samples 1, 8-9, and 11, see Table 2 below for sample concentrations) had been dissolved was added to each petri dish, and the cells were incubated for 24 hours at 37°C and 5% CO2. As a control, the cells were incubated in the same manner using KGM medium without the addition of samples. After the incubation, the medium was removed, and total RNA was extracted using ISOGEN II (Nippon Gene Co., Ltd., Cat. No. 311-07361). The amount of each RNA was measured using a spectrophotometer, and total RNA was adjusted to 200 ng / μL.

[0157] Using this total RNA as a template, the expression levels of mRNA for AQP3 and GAPDH, an internal standard, were measured. Detection was performed by real-time 2-step RT-PCR reaction using a real-time PCR device Smart Cycler (Cepheid) and a TaKaRa SYBR PrimeScript RT-PCR kit (Perfect Real Time) (Takara Bio, code No. RR063A). The expression level of AQP3mRNA was calculated based on the total RNA samples prepared from cells cultured with and without the addition of the test sample, and the correction value was calculated using the GAPDH value. The AQP3mRNA expression promotion rate (%) was calculated from the obtained values ​​using the following formula.

[0158] AQP3 mRNA expression promotion rate (%) = A / B × 100 Each term in the formula represents the following: A: Correction value when test sample is added B: Correction value without sample The results are shown in Table 2.

[0159] [Table 2]

[0160] As shown in Table 2, branbuline A (sample 1), isostrictinin (sample 8), rubusoside (sample 9), and sweet tea extract (sample 11) were confirmed to have excellent AQP3 mRNA expression promoting effects.

[0161] [Test Example 3] Plaque formation inhibitory effect test Plaque formation inhibition tests were performed on branbuline A (sample 1), branbuline B (sample 2), branbuline C (sample 3), branbuline D (sample 4), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose (sample 5), rubusaviin A (sample 6), and isostrictinin (sample 8) obtained in the manufacturing examples using the following test method.

[0162] 5.35 mL of Brain Heart Infusion Broth (manufactured by Nissui Pharmaceutical Co., Ltd.) containing 2% sucrose was added to a pre-weighed test tube, and heat sterilization was performed. 0.15 mL of a solution (solvent: distilled water) of the test sample (samples 1 to 6 and 8, see Table 3 below for the final concentration of each sample) and 0.5 mL of a culture solution of Streptococcus mutans 6715 were added to the test tube, and the tubes were cultured at 37°C for 19 hours. As a control, distilled water was used instead of the test sample (no sample added) and the tubes were cultured in the same manner. After the culture was completed, the supernatant was gently removed, and the plaque-like deposits on the test tube walls were washed three times with distilled water and then dried at 105°C for 5 hours. Finally, the test tubes were weighed to determine the dry mass of the plaque-like deposits in the tubes. From the obtained values, the plaque formation inhibition rate (%) was calculated using the following formula.

[0163] Plaque formation inhibition rate (%) = (1-w / W) x 100 Each term in the formula represents the following: w: dry mass of plaque-like deposits when test sample is added W: Dry mass of plaque-like deposits without adding sample The results are shown in Table 3.

[0164] [Table 3]

[0165] As shown in Table 3, branbuline A (sample 1), branbuline B (sample 2), branbuline C (sample 3), branbuline D (sample 4), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose (sample 5), rubusaviin A (sample 6), and isostrictinin (sample 8) were confirmed to have excellent plaque formation inhibitory effects.

[0166] [Test Example 4] Serine palmitoyltransferase (SPT) mRNA expression promoting effect test The SPT mRNA expression promoting effect of branbuline A (sample 1), branbuline B (sample 2), branbuline D (sample 4), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose (sample 5), brevifoline carboxylic acid (sample 7), isostrictinin (sample 8), and rubusoside (sample 9) obtained in the manufacturing examples, as well as ellagic acid (sample 10), and sweet tea extract (sample 11) were tested as follows.

[0167] Normal human neonatal epidermal keratinocytes (NHEK) were cultured in a growth medium for normal human epidermal keratinocytes (KGM) at 80 cm 2 The cells were pre-cultured in a flask at 37°C and 5% CO2, and then harvested by trypsinization. The harvested cells were diluted to 20 × 10 4 After diluting with KGM medium to a cell density of 10 cells / mL, 2 mL of the cells were seeded (40 × 10 4 The cells were cultured at 37℃ and 5% CO2 for 24 hours.

[0168] After the incubation, the medium was removed, and 2 mL of KGM medium in which test samples (samples 1-2, 4-5, and 7-11, see Table 4 below for sample concentrations) had been dissolved was added to each petri dish, and the cells were incubated at 37°C and 5% CO2 for 24 hours. As a control, the cells were incubated in the same manner using KGM medium without sample addition. After the incubation, the medium was removed, and total RNA was extracted using ISOGEN II (Nippon Gene Co., Ltd., Cat. No. 311-07361). The amount of each RNA was measured using a spectrophotometer, and total RNA was adjusted to 200 ng / μL.

[0169] Using this total RNA as a template, the mRNA expression levels of SPT and GAPDH, an internal standard, were measured. Detection was performed by real-time 2-step RT-PCR reaction using a real-time PCR device Smart Cycler (Cepheid) and a TaKaRa SYBR PrimeScript RT-PCR kit (Perfect Real Time) (Takara Bio, code No. RR063A). The expression level of SPT was calculated based on the total RNA samples prepared from cells cultured with and without the addition of the test sample, and the correction value was calculated using the GAPDH value. From the obtained values, the SPT mRNA expression promotion rate (%) was calculated using the following formula.

[0170] SPT mRNA expression promotion rate (%) = A / B × 100 Each term in the formula represents the following: A: Correction value when test sample is added B: Correction value without sample The results are shown in Table 4.

[0171] [Table 4]

[0172] As shown in Table 4, it was confirmed that branbuline A (sample 1), branbuline B (sample 2), branbuline D (sample 4), 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisoruboylglucose (sample 5), brevifoline carboxylic acid (sample 7), isostrictinin (sample 8), rubusoside (sample 9), ellagic acid (sample 10), and sweet tea extract (sample 11) all have excellent SPT mRNA expression promoting effects.

[0173] [Formulation example 1] A mouthwash for preventing dry mouth having the following composition was prepared by a conventional method. Branbriin A 0.05 parts by mass Branbriin B 0.05 parts by mass Dicalcium phosphate 45.0 parts by mass Sodium carboxymethylcellulose 1.0 parts by mass Glycerin 20.0 parts by weight Sodium lauryl sulfate 2.0 parts by weight Fragrance 1.0 parts by mass Glycyrrhizin 0.1 parts by mass Purified water 30.0 parts by mass

[0174] [Formulation example 2] A candy for preventing dry mouth having the following composition was produced by a conventional method. Branbriin C 0.05 parts by mass Lubusabiin A 0.05 parts by weight Brevifolin carboxylic acid 0.05 parts by mass Sucrose 70.0 parts by weight Starch syrup 30.0 parts by weight Citric acid 1.0 parts by mass Fragrance 0.1 part by mass Water 20.0 parts by mass

[0175] [Formulation example 3] A chewing gum for preventing dry mouth having the following composition was produced by a conventional method. Branbriin D 0.05 parts by weight Rubusoside 0.05 parts by mass Chewing gum base 20.0 parts by weight Sucrose 55.0 parts by weight Starch syrup 20.0 parts by weight Softener 4.0 parts by weight Fragrance 0.8 parts by mass

[0176] [Formulation example 4] A chocolate for preventing dry mouth having the following composition was produced by a conventional method. Sweet tea extract 0.1 part by mass Chocolate 45.0 parts by weight Sucrose 15.0 parts by weight Cocoa butter 20.0 parts by weight Whole milk powder 25.0 parts by mass

[0177] [Formulation example 5] An anti-caries toothpaste having the following composition was prepared in a conventional manner. Isostrictinine 0.1 parts by mass 2,3-O-Hexahydroxydiphenoyl- 4,6-O-Sangisoruboylglucose 0.1 parts by mass Calcium carbonate 39.0 parts by mass Sorbitol 22.0 parts by weight Carboxymethyl cellulose 1.1 parts by mass Sodium lauryl sulfate 1.3 parts by weight Saccharin 0.1 parts by weight Fragrance 1.0 parts by mass Chlorhexidine hydrochloride 0.01 parts by mass Purified water 35.0 parts by mass [Industrial Applicability]

[0178] The novel ellagitannin of the present invention can be used as an active ingredient of an AQP5 mRNA expression promoter, an AQP3 mRNA expression promoter, a plaque formation inhibitor or an SPT mRNA expression promoter, and can also be incorporated into oral compositions or foods and beverages.

[0179] In addition, the AQP5 mRNA expression promoter, AQP3 mRNA expression promoter, plaque formation inhibitor and SPT mRNA expression promoter of the present invention can greatly contribute to the prevention, treatment or amelioration of dental caries; the prevention, treatment or amelioration of xerostomia; improvement of the skin barrier function, etc.

Claims

1. An aquaporin 5 mRNA expression promoter comprising one or more active ingredients selected from the group consisting of 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, brevifolin carboxylic acid, isostrictinin, and rubusoside.

2. An aquaporin 3 mRNA expression promoter characterized by having isostrictinine and / or rubusoside as active ingredients.

3. A plaque formation inhibitor comprising as an active ingredient one or more members selected from the group consisting of 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, rubusaviin A, and isostrictinin.

4. A serine palmitoyltransferase mRNA expression promoter comprising as an active ingredient one or more selected from the group consisting of 2,3-O-hexahydroxydiphenoyl-4,6-O-sanguisorvoylglucose, brevifoline carboxylic acid, isostrictinine, rubusoside, and ellagic acid.

5. An aquaporin 5 mRNA expression promoter characterized by having an extract from sweet tea leaves as an active ingredient.

6. An aquaporin 3 mRNA expression promoter characterized by having sweet tea leaf extract as an active ingredient.

7. A serine palmitoyltransferase mRNA expression promoter comprising an extract from sweet tea leaves as an active ingredient.

Citation Information

Patent Citations

  • Oral cavity agent

    JP2000178158A

  • Glucosyltransferase inhibitor, plaque formation inhibitor, antibacterial agent, agent for oral cavity, and beverage or food for preventing caries

    JP2005082568A

  • Ceramide synthesis promoter

    JP2006111560A

  • Skin care preparation

    JP2006206513A

  • Skin cosmetic and hair care cosmetic

    JP2007099698A